Tag - BIAF

Developments

bioAffinity initiates longitudinal study for CyPath Lung

bioAffinity Technologies (NASDAQ: BIAF; BIAFW) has initiated a planned large-scale, longitudinal clinical study for CyPath Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer. The 2,000...

March 11, 2026

Feature

bioAffinity rolling out CyPath for early detection of lung cancer

bioAffinity Technologies (NASDAQ:BIAF) is rolling out CyPath Lung, an accurate, non-invasive and cost-effective test for the early detection of lung cancer, in the U.S. Southwest before a staged nationwide launch.

March 14, 2023

Tag - BIAF

bioAffinity initiates longitudinal study for CyPath Lung

bioAffinity rolling out CyPath for early detection of lung cancer

Subscribe